2m 2m 2m 2m 2m 2m 2m
NEUROGENE (NGNE)
NASDAQ
$31.75+$0.89 (+2.88%)
Price as of Jun 23, 2026 7:08 PM EDT- $509.6MMarket Cap
- 79.42%1-Year Change
- BiotechnologyIndustry
NEUROGENE (NGNE)
$31.75+$0.89 (+2.88%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 925,000 N/A | N/A N/A | 1.6M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 925,000 N/A | 0 -100.00% | 1.6M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -75.0M +23.14% | -60.9M +37.22% | -44.4M +7.94% | -41.1M +5.02% | |
Depreciation and Amortization Expense | 3.0M -4.76% | 3.2M -2.05% | 3.3M +108.97% | 1.6M +19.53% | |
Total Operating Expenses | 103.3M +23.70% | 83.5M +50.28% | 55.6M -5.95% | 59.1M +174.41% | |
Operating Profit | -103.3M +25.09% | -82.6M +48.62% | -55.6M -5.95% | -59.1M -2.64% | |
Interest Income | 11.5M +36.38% | 8.5M +186.92% | 3.0M N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -12,000 N/A | N/A N/A | |
Interest Income and Expense and Net | 11.5M +36.38% | 8.5M +188.09% | 2.9M N/A | 0 N/A | |
Total Nonoperating Income and Expense | 1.7M +190.07% | 574,000 +4,683.33% | 12,000 +128.57% | -42,000 -800.00% | |
Income before Taxes | -103.3M +25.09% | -82.6M +48.62% | -55.6M -5.95% | -59.1M -2.64% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | N/A N/A | |
Extraordinary Items | 120,000 +31.87% | 91,000 N/A | N/A N/A | N/A N/A | |
Net Income | -90.4M +20.24% | -75.1M +106.91% | -36.3M -36.90% | -57.6M -5.17% | |
Net Income from Continuing Operations Applicable to Common | -90.4M +20.24% | -75.1M +106.91% | -36.3M -36.90% | -57.6M -5.17% | |
Basic EPS and Net Income | -4.24 -0.93% | -4.28 -96.35% | -117.28 +11,176.92% | -1.04 -5.45% | |
Diluted EPS and Net Income | -4.24 -0.93% | -4.28 -96.35% | -117.28 +11,176.92% | -1.04 -5.45% | |
Basic Weighted Average Shares | 21.3M +21.40% | 17.6M +4,022.79% | 426,097 -99.23% | 55.2M +0.33% | |
Diluted Weighted Average Shares | 21.3M +21.40% | 17.6M +1,961.39% | 852,194 -98.46% | 55.2M +0.33% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 103.8M -23.97% | 136.6M -7.84% | 148.2M +291.19% | 37.9M -73.41% | |
Short-Term Investments | 165.2M -6.06% | 175.8M +259.20% | 48.9M -16.33% | 58.5M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 269.0M -13.89% | 312.4M +58.45% | 197.2M +104.55% | 96.4M -32.35% | |
Total Current Assets | 271.8M -13.98% | 315.9M +57.69% | 200.3M +102.10% | 99.1M -31.15% | |
Accumulated Depreciation | 14.1M +26.30% | 11.2M +39.48% | 8.0M +171.31% | 3.0M +80.55% | |
Property and Plant and Equipment and Net | 12.8M -17.05% | 15.4M -10.20% | 17.2M +178.66% | 6.2M -4.48% | |
Total Long-Term Assets | 1.0M +5.95% | 975,000 +27.62% | 764,000 -18.38% | 936,000 -51.45% | |
Total Assets | 288.6M -14.04% | 335.7M +50.84% | 222.6M +91.96% | 115.9M -28.98% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 16.4M +8.27% | 15.2M -34.02% | 23.0M +107.67% | 11.1M +28.09% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 51,000 0.00% | 51,000 -74.88% | 203,000 -98.03% | 10.3M -11.75% | |
Total Liabilities | 23.7M -6.46% | 25.4M -30.63% | 36.5M +69.08% | 21.6M +5.97% | |
Retained Earnings | -352.6M +34.45% | -262.3M +40.15% | -187.2M -58.51% | -451.1M +14.63% | |
Total Stockholders Equity | 264.9M -14.66% | 310.4M +66.85% | 186.0M +97.20% | 94.3M -33.97% | |
Total Shares Outstanding | 15.5M +4.28% | 14.9M +15.84% | 12.8M -69.93% | 42.6M +0.45% | |
Cash Flow | |||||
Cash from Operating Activities | -77.2M +9.31% | -70.6M +37.30% | -51.4M +12.75% | -45.6M -4.10% | |
Capital Expenditures | 1.2M +46.41% | 808,000 +151.71% | 321,000 -71.08% | 1.1M -65.98% | |
Cash from Investing Activities | 14.0M +111.18% | -125.3M -588.59% | 25.6M +143.35% | -59.1M +1,712.26% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 30.4M -83.47% | 184.1M +99.03% | 92.5M +57,342.24% | 161,000 -78.01% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -8,930.27% N/A | N/A N/A | -3,735.59% N/A | |
Return on Assets | -28.94% +7.52% | -26.92% +25.46% | -21.46% -47.96% | -41.23% +26.96% | |
Return on Equity | -31.41% +3.75% | -30.28% +16.86% | -25.91% -46.62% | -48.53% +33.57% | |
Revenue Growth | -100.00% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 16.56 -20.55% | 20.84 +139.00% | 8.72 -2.69% | 8.96 -46.25% | |
Cash Ratio | 6.33 -29.78% | 9.01 +39.68% | 6.45 +88.36% | 3.43 -79.24% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow